Monoclonal Antibody Therapies: Evolving into a $30 billion market

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2005-04-15

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

The monoclonal antibody market is one of the fastest growing and most lucrative sectors of the pharmaceutical industry, with exceptional 48.1% growth between 2003 and 2004. It has the potential to triple in value over the next six years and reach $30.3 billion in 2010, driven by technological evolution from chimeric and humanized to fully human antibodies.


Scope

  • Global forecasts for all products launching by 2010, split by therapy area and technology type, including actual 2004 company-reported sales
  • Analysis of the portfolio and pipelines for 101 companies, covering 291 active development programs, including 10 in-depth profiles of key companies
  • Strategic evaluation of key market issues and future opportunities for companies to fully capitalize on the market
  • Evaluation of key antibody engineering technologies, including in-depth profiles of the 11 leading platforms


    • Report Highlights
    The mAbs market is expected to almost triple in value over the next six years from $10.3 billion in 2004 to $30.3 billion. Oncology products will continue to dominate the market. However, sales of arthritis, immune and inflammatory disorders (AIID) products are forecast to grow strongly and account for 40.1% of the market by 2010.

    The development focus of the industry is moving away from murine and chimeric antibodies, to humanized and, in particular, fully human technologies. A wave of fully human products are expected to launch from 2007 onwards, accounting for 12 of the 20 launches between 2007 and 2010.

    Roche and Genentech dominate the mAbs market, with a combined market share of 44.9% in 2004, although this is forecast to slip to 35.7% in 2010. Datamonitor identified just 17 companies with direct sales of monoclonal antibodies in 2004, but this figure is expected to more than double to 36 in 2010, as new products and companies flood the market.


    Reasons to Purchase

  • Validate your analysis of the market by company, therapy area and technology, with Datamonitor's sales forecasts for all antibodies launching by 2010
  • Identify key therapeutic and technological trends to capitalize on opportunities in the monoclonal antibody sector
  • Benchmark your corporate strategy and alliance networks against key competitors to optimize your future business development

    • Table of Contents

    Other users found this report page using the following search terms: antibodies antibody monoclonal antibody antibodies market companies technology therapies development sales marketed

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.